Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

BIOVAXYS ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

Each Unit consist of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until December 18, 2026, being the date that is 24 months from the date of issue. Each Unit consist of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a…

Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034…

Key Takeaways from the Germ Cell Tumors Market Report Key Takeaways from the Germ Cell Tumors Market Report Discover which therapies are expected to grab the major Germ Cell Tumors market share @Germ Cell Tumors Market Report Germ Cell Tumors Overview Germ cell tumors are a rare type of growth that originates from germ cells, the cells responsible for developing into sperm in males and eggs in females. These tumors can be benign or malignant and often develop in the gonads,...

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize…

The Frost & Sullivan Global Enabling Technology Award recognizes companies that have developed a pioneering technology that enhances current products and enables the development of new products and applications. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. The Frost & Sullivan Global Enabling Technology Award recognizes companies that have developed…

The acquisition of Catalent by Novo Holdings, and the related acquisition by…

Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US).The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see thecompany announcement here...

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application…

GZR18, as a GLP-1 receptor agonist, can delay gastric emptying by activating GLP-1 receptors expressed on the gastrointestinal tract; and enhance satiety and suppress appetite by activating GLP-1 receptors in the hypothalamus and other parts, thereby reducing the patient's weight. GZR18 injection is the first bi-weekly GLP-1 mono-agonist formulation. Current clinical data has demonstrated weight loss effects comparable to or even better than multi-target once-weekly GLP-1 formulations, providing…

Apollo Care Secures Growth Equity Investment from Flexpoint Ford to Accelerate…

Flexpoint Ford is a private equity firm focused on the healthcare and financial services sectors, offering tailored and flexible capital solutions to its partner companies. The firm has approximately $8.2 billion of assets under management. Flexpoint Ford is a private equity firm focused on the healthcare and financial services sectors, offering tailored and flexible capital solutions to its partner companies. The firm has approximately$8.2 billionof assets under management. "Flexpoint's...

Bridge to Life Acquires VitaSmart™ Hypothermic Oxygenated Machine Perfusion…

This acquisition marks a significant milestone in Bridge to Life's efforts to advance transplant medicine. Over 5,0001 successful liver perfusions have been conducted globally using Hypothermic Oxygenated Perfusion (HOPE) in combination with the VitaSmart™ system, demonstrating its effectiveness in organ preservation. This acquisition marks a significant milestone in Bridge to Life's efforts to advance transplant medicine. Over 5,000 1successful liver perfusions have been conducted globally...

Bioplastics: Paving the Way to Meet EU Packaging and Packaging Waste Regulation…

European Bioplastics (EUBP) welcomes the adoption of the European Union's ambitious Packaging and Packaging Waste Regulation (PPWR). The adoption by the Council on 16 December represents the final step in the co-legislative procedure before its entry into force. The PPWR places significant emphasis on sustainable packaging solutions, with biobased plastics emerging as a key enabler of the EU's circular economy and climate neutrality goals.“ Biobased plastics will play a pivotal role in...

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology…

This is the aim of the new initiative at the Technical University of Denmark (DTU): Novo Nordisk Foundation Biotechnology Research Institute for the Green Transition (BRIGHT). The new initiative aims to create knowledge and solutions that can be transformed into efficient bioproduction, making a significant contribution to the green transition of society. This is the aim of the new initiative at theTechnical University of Denmark(DTU): Novo Nordisk Foundation Biotechnology Research...

Implantica announces two new RefluxStop™ University Hospitals in Spain, leading…

Dr. Viana says, "We are waking up to a new era of surgical treatment for GERD with the introduction of RefluxStop, and it's very exciting. Many of my GERD patients were not candidates for the traditional surgical treatments of the past and had the added burden of not responding well to medication for GERD. I am very impressed with the long-term results of the highly regarded 5-year RefluxStop CE mark clinical study. Now, I can offer my patients a new and proven option to treat their painful…

ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY

Issuer name: Ultimovacs ASA Ex. date: 18 December 2024 Type of corporate action: Potential repair offering Other information: Any repair offering is subject to the prior publication of a prospectus in accordance with applicable legislation. This information is published in accordance with the requirements of the Continuing Obligations.

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Dr. Michael Thurn, Managing Director and Chief Executive Officer of Neurizon, commented:"The submission of our IND application to the FDA represents a critical milestone in Neurizon's mission to address the devastating impacts of ALS. The application represents the culmination of several years of research and development and contains many elements that are ultimately required for our New Drug Application (NDA) submission. Our team has worked tirelessly around the clock to produce this…

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec…

Roche launches its cobas ®Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical mass spectrometry testing offers unparalleled sensitivity and specificity, providing clinicians with additional diagnostic insights 1 cobas Mass Spec solution will offer a fully automated, integrated and standardised workflow with IVDR-compliant assaysBasel, 18 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark approval...

NMD Pharma publishes new data on the role of ClC-1 inhibition in…

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in theAnnals of Clinical and Translational NeurologyResults from the ESTABLISH 1observational study confirms that neuromuscular junction (NMJ) dysfunction is an underappreciated disease characteristic in patients with Charcot-Marie-Tooth disease (CMT) types 1 and 2 affecting muscle function in patientsAdditionally, results from preclinical studies provide proof-of-mechanism for recovery of...

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2…

The indirect treatment comparison concluded that patients in the 15-HMedIdeS-09 study treated with imlifidase plus IVIg returned to independently walking 6 weeks sooner when compared to severe GBS patients in the IGOS real-world comparator group treated with IVIg. Additionally, patients in the 15-HMedIdeS-09 study experienced statistically significant improvement across several clinically meaningful measures at multiple time points as compared to the IGOS real-world comparator group including…

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with…

Participants canregister herefor the virtual event airing 9:00am ET / 3:00pm CETPARIS and CAMBRIDGE, Mass., Dec.17, 2024(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics,"...

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our…

BIOVAXYS ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034…

Spineway wins new approvals in Vietnam and registers initial orders

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction…

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology…

Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR |…

Therapeutic Drug Monitoring Market to Hit USD 3.44 Billion by 2029 with 8.4%…

Orion and Abilita Therapeutics announce research collaboration and option to…

All Neoss® Group products are now certified under the EU Medical Device…

DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize…

The acquisition of Catalent by Novo Holdings, and the related acquisition by…

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application…

Apollo Care Secures Growth Equity Investment from Flexpoint Ford to Accelerate…

Bridge to Life Acquires VitaSmart™ Hypothermic Oxygenated Machine Perfusion…

Bioplastics: Paving the Way to Meet EU Packaging and Packaging Waste Regulation…

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology…

Implantica announces two new RefluxStop™ University Hospitals in Spain, leading…

ULTI – EX. RIGHT TO PARTICIPATE IN POTENTIAL REPAIR OFFERING TODAY

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec…

NMD Pharma publishes new data on the role of ClC-1 inhibition in…

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2…

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with…

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare…